To this regard, recent clinical studies have described limited efficacy of ICIs, targeting mainly cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed-cell death-1 (PD-1) or its ligand PD-L1, in NSCLC harboring EGFR mutations and TKIs naive (12). The gene discussed is CD274; the disease is non-small cell lung carcinoma.